69559-11-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Aminopentyl(ethyl)amino)ethanol is used as a pharmaceutical intermediate for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be incorporated into the development of new drugs, potentially leading to innovative treatments and therapies.

InChI:InChI=1/C9H22N2O/c1-3-11(7-8-12)6-4-5-9(2)10/h9,12H,3-8,10H2,1-2H3

Upstream product

• 74509-79-8 5-(N-ethyl-N-2-hydroxyethylamine)-2-pentanone 
• 159346-86-8 R(-)-5--2-pentanamine 
• 517-23-7 3-acetyl-2-oxo-4,5-dihydrofuran 
• 3695-29-2 5-iodo-2-pentanone 

Downstream Products

• 118-42-3 hydroxychloroquine 
• 747-36-4 Plaquenil 
• 747-36-4 (S)-hydroxychloroquine sulfate 
• 747-36-4 R-(-)-hydroxychloroquine sulfate 
• 137433-23-9 (S)-Hydroxychloroquine 
• 137433-23-9 (R)-Hydroxychloroquine 

Relevant academic research and scientific papers

Application of chiral chloroquine, hydroxychloroquine or salt of the chiral chloroquine and hydroxychloroquine as anti-coronavirus drug target 3CL hydrolase inhibitor for reducing cardiotoxicity

The invention discloses an application of chiral chloroquine, hydroxychloroquine or pharmaceutically acceptable salts of the chiral chloroquine and hydroxychloroquine in preparation of drugs used forpreventing and/or treating coronavirus pneumonia by using a coronavirus key drug target 3CL hydrolase (Mpro) as an action target. The chiral chloroquine and hydroxychloroquine have high bonding strength with the Mpro causing inflammation of the lung and the like; the activity of the Mpro can be significantly inhibited; and the chiral chloroquine and hydroxychloroquine are indicated to have the effect of preventing and treating pneumonia caused by coronaviruses and be able to be used as anti-pneumonia drugs. Through evaluation on the inhibitory activity of an hERG potassium ion channel, the concentration at which the chloroquine, hydroxychloroquine and enantiomers of the chloroquine and hydroxychloroquine are likely to generate cardiotoxicity to the hERG potassium ion channel is provided. The chiral chloroquine and hydroxychloroquine are prepared through chiral high-performance liquid chromatography and chiral synthesis; S-configuration chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine can be selected as a drug independently, or form a pharmaceutical composition for treating diseases caused by the coronaviruses; and due to higher activity and low cardiotoxicity of the chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine, the administration dosage range is greatly widened.

Method for continuously producing 5-(N-ethyl-N-2-hydroxyethyl amine)-2-pentylamine

The invention discloses a method for continuously producing 5-(N-ethyl-N-2-hydroxyethyl amine)-2-pentylamine, and the method comprises the following steps: in a reducing atmosphere, continuously inputting a mixed solution containing 5-(N-ethyl-N-2-hydroxyethyl amine)-2-pentanone and a nitrogen source into a fixed bed reactor filled with a supported nano nickel-based catalyst; carrying out reductive amination reaction under the conditions that the pressure is 0.2 to 2MPa, the temperature is 80 to 140 DEG C and the feeding mass space velocity is 0.2 to 1.0 h , so as to prepare the 5-(N-ethyl-N-2-hydroxyethyl amine)-2-pentylamine. According to the method provided by the invention, the continuous production of the 5-(N-ethyl-N-2-hydroxyethyl amine)-2-pentylamine can be realized under theaction of the supported nano Ni catalyst and a nitrogen source; meanwhile, the catalyst is low in cost, high in production efficiency, good in stability, simple to operate, low in production cost andconvenient for industrial production.

HIGH-YIELDING CONTINUOUS FLOW SYNTHESIS OF ANTIMALARIAL DRUG HYDROXYCHLOROQUINE

Cost effective, semi-continuous flow methods and systems for synthesizing the antimalarial drug hydroxychloroquine (HCQ) in high yield are provided. The synthesis method that uses simple, inexpensive reagents to obtain the crucial intermediate 5-(ethyl(2-hydroxyethyl)- amino)pentan-2-one, vertical-integration of the starting material 5-iodopentan-2-one and the integration of continuous stirred tank reactors.

High-yielding continuous-flow synthesis of antimalarial drug hydroxychloroquine

Numerous synthetic methods for the continuous preparation of fine chemicals and active pharmaceutical ingredients (API's) have been reported in recent years resulting in a dramatic improvement in process efficiencies. Herein we report a highly efficient continuous synthesis of the antimalarial drug hydroxychloroquine (HCQ). Key improvements in the new process include the elimination of protecting groups with an overall yield improvement of 52% over the current commercial process. The continuous process employs a combination of packed bed reactors with continuous stirred tank reactors for the direct conversion of the starting materials to the product. This high-yielding, multigram-scale continuous synthesis provides an opportunity to achieve increase global access to hydroxychloroquine for treatment of malaria.